GenesisCare Collaborates with SeeTreat to Enhance Cancer Care in Australia

GenesisCare and SeeTreat Partnership

In an important development for cancer care in Australia, GenesisCare, a leading provider of radiation oncology, has announced a collaboration with innovative technology company SeeTreat. This partnership aims to introduce Offline Adaptive Monitoring to over 40 radiation oncology centers across the country, starting in July 2026. The initiative is aimed at giving suitable cancer patients access to the latest advancements in adaptive treatment evaluation through SeeTreat's ART.1 software.

Dr. Marcus Dreosti, the Chief Medical Officer at GenesisCare, articulated the need for this technology, stating that while radiation treatment remains an effective cancer therapy, patients often experience unwanted side effects due to changes in their anatomy throughout the treatment process. "Optimizing treatment after it has begun, known as 'adaptive radiotherapy', can be both complex and labor-intensive," he explained. This collaboration with SeeTreat promises to simplify this process and make it more accessible, benefiting patients in the network.

GenesisCare's interest in the ART.1 tool was driven by results from a comprehensive study involving 64 patients diagnosed with head and neck, breast, and prostate cancers. The study focused on assessing the tool's ability to standardize and enhance adaptive workflows, ultimately providing actionable insights for clinicians at a crucial juncture.

Dr. Melanie Jackson, a Radiation Oncologist, praised the ART.1 software for its user-friendly interface. She noted, "This tool helps me identify which patients could benefit from tailored treatment plans and determine the best time for those changes to be made." The efficiency offered by ART.1 allows clinical teams to leverage their resources effectively, ensuring that efforts are maximally directed toward achieving optimal patient outcomes.

Echoing Dr. Jackson's sentiments, Dr. Trang Nguyen, CEO and Founder of SeeTreat, expressed his excitement about working with GenesisCare, describing it as a patient-centric and pioneering organization. "The commitment of GenesisCare's staff to delivering the best care possible is admirable, and we are proud to collaborate with them on this important initiative," he stated.

The ART.1 software has already achieved significant regulatory approvals, including UKCA and CE marks, as well as Australian ARTG registration. It is currently under review for FDA approval. SeeTreat was established in 2023, demonstrating a commitment to leveraging technology to alleviate the burden of cancer through improved treatment accuracy and quality.

GenesisCare is an Australian-based organization that specializes in radiation therapy and is expanding into medical oncology and personalized medicine. With a strong emphasis on innovation, their dedicated research team operates globally to bring cutting-edge clinical solutions to patients locally. Each year, more than 35,000 individuals trust GenesisCare for their cancer care across more than 50 locations in Australia.

This partnership between GenesisCare and SeeTreat not only embodies a significant leap forward in cancer treatment technology but also reinforces the commitment of both organizations to improve patient care. By integrating innovative solutions, they aim to transform the way cancer care is delivered across Australia, ultimately setting a new standard in the field.